| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Servei de Pneumologia, 3 Neurofisiologia Clínica and 4 Otorrinolaringologia, Hospital General Vall d'Hebron and 2 Laboratori de Bioestadística i Epidemiologia, Universitat Autònoma de Barcelona, Barcelona, Spain
CORRESPONDENCE: S. Martí, Servei de Pneumologia, Hospital General Vall d'Hebron, Passeig Vall d'Hebron, 119–129, 08035, Barcelona, Spain. Fax: 34 932746083. E-mail: smartib@hg.vhebron.es
Keywords: cardiovascular diseases, mortality, sleep apnoea syndrome, therapeutics
Received: January 4, 2002
Accepted July 12, 2002
This study was financed in part by a grant from Agència d'Avaluació de Tecnologia Mèdica (Servei Català de la Salut).
The aim of this study was to determine mortality in patients with sleep apnoea/hypopnoea syndrome (SAHS) according to the treatments employed and comorbidity.
An historical cohort of patients with SAHS diagnosed at a university hospital between 1982 and 1992 and followed until 1996 was studied. From a total of 475 SAHS patients, 444 (94%), with a mean±sd apnoea/hypopnoea index at diagnosis of 55±27, were located and included in the study. SAHS treatments employed were: surgery (88), weight loss (134), continuous positive airway pressure (124) and 98 patients were not treated.
By the end of follow-up, 49 patients had died. According to Cox regression analysis, mortality in treated patients was lower than in those not treated, but higher in those with a history of severe chronic obstructive pulmonary disease. Mortality in nontreated patients compared with that of the general population, adjusted for age and sex, showed excessive mortality, which decreased in treated patients. Stratification by age showed a greater mortality rate ratio in patients <50 yrs. These findings were maintained when mortality from cardiovascular causes was compared.
In conclusion, a rise in mortality was found in nontreated sleep apnoea/hypopnoea syndrome patients compared with the general population, whereas mortality in those treated for sleep apnoea/hypopnoea syndrome did not differ significantly from that of the general population.
This article has been cited by other articles:
|
|
 |
|
  M. H. Sanders, J. M. Montserrat, R. Farre, and R. J. Givelber Positive Pressure Therapy: A Perspective on Evidence-based Outcomes and Methods of Application Proceedings of the ATS, February 15, 2008; 5(2): 161 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Buchner, B. M. Sanner, J. Borgel, and L. C. Rump Continuous Positive Airway Pressure Treatment of Mild to Moderate Obstructive Sleep Apnea Reduces Cardiovascular Risk Am. J. Respir. Crit. Care Med., December 15, 2007; 176(12): 1274 - 1280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lavie Mortality in sleep apnoea syndrome: a review of the evidence Eur. Respir. Rev., December 1, 2007; 16(106): 203 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Mokhlesi and A. Tulaimat Recent Advances in Obesity Hypoventilation Syndrome Chest, October 1, 2007; 132(4): 1322 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Parati, C. Lombardi, and K. Narkiewicz Sleep apnea: epidemiology, pathophysiology, and relation to cardiovascular risk Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2007; 293(4): R1671 - R1683. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Hernandez, J. Abreu, P. Abreu, A. Castro, and A. Jimenez Nocturnal melatonin plasma levels in patients with OSAS: the effect of CPAP Eur. Respir. J., September 1, 2007; 30(3): 496 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Basner Continuous Positive Airway Pressure for Obstructive Sleep Apnea N. Engl. J. Med., April 26, 2007; 356(17): 1751 - 1758. [Full Text] [PDF]
|
|
|
|
|
|
W. T. McNicholas, M. R. Bonsignore, and the Management Committee of EU COST ACTION B26 Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities Eur. Respir. J., January 1, 2007; 29(1): 156 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Kezirian, E. M. Weaver, B. Yueh, S. F. Khuri, J. Daley, and W. G. Henderson Risk factors for serious complication after uvulopalatopharyngoplasty. Arch Otolaryngol Head Neck Surg, October 1, 2006; 132(10): 1091 - 1098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Minoguchi, T. Yokoe, A. Tanaka, S. Ohta, T. Hirano, G. Yoshino, C. P. O'Donnell, and M. Adachi Association between lipid peroxidation and inflammation in obstructive sleep apnoea. Eur. Respir. J., August 1, 2006; 28(2): 378 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. K. Yaggi, J. Concato, W. N. Kernan, J. H. Lichtman, L. M. Brass, and V. Mohsenin Obstructive Sleep Apnea as a Risk Factor for Stroke and Death. N. Engl. J. Med., November 10, 2005; 353(19): 2034 - 2041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Minoguchi, T. Yokoe, T. Tazaki, H. Minoguchi, A. Tanaka, N. Oda, S. Okada, S. Ohta, H. Naito, and M. Adachi Increased Carotid Intima-Media Thickness and Serum Inflammatory Markers in Obstructive Sleep Apnea Am. J. Respir. Crit. Care Med., September 1, 2005; 172(5): 625 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Campos-Rodriguez, N. Pena-Grinan, N. Reyes-Nunez, I. De la Cruz-Moron, J. Perez-Ronchel, F. De la Vega-Gallardo, and A. Fernandez-Palacin Mortality in Obstructive Sleep Apnea-Hypopnea Patients Treated With Positive Airway Pressure Chest, August 1, 2005; 128(2): 624 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Doherty, J. L. Kiely, V. Swan, and W. T. McNicholas Long-term Effects of Nasal Continuous Positive Airway Pressure Therapy on Cardiovascular Outcomes in Sleep Apnea Syndrome Chest, June 1, 2005; 127(6): 2076 - 2084. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Lavie, L. Lavie, and P. Herer All-cause mortality in males with sleep apnoea syndrome: declining mortality rates with age Eur. Respir. J., March 1, 2005; 25(3): 514 - 520. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
